Covered recipient · General Payments record
HELEN O ONORIODE
Allopathic & Osteopathic Physicians Obstetrics & Gynecology
General Payments · PY2018–2024
$8,301.29
- Reported across 34 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $1,200.00 | 5 |
| Food and Beverage | $318.73 | 12 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| MIMEDX Group, Inc. | $1,200.00 | 5 |
| Astellas Pharma US Inc | $147.96 | 5 |
| Organon LLC | $50.50 | 2 |
| PFIZER INC. | $44.83 | 2 |
| CooperSurgical, Inc. | $31.44 | 1 |
| Integra LifeSciences Corporation | $22.37 | 1 |
| Novo Nordisk AS | $21.63 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Astellas Pharma US Inc | $110.27 | 02/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139377074 | CMS |
| Astellas Pharma US Inc | $10.97 | 07/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139276432 | CMS |
| Astellas Pharma US Inc | $10.49 | 07/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139270624 | CMS |
| Astellas Pharma US Inc | $10.40 | 09/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139398353 | CMS |
| Astellas Pharma US Inc | $5.83 | 11/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139430414 | CMS |
| CooperSurgical, Inc. | $31.44 | 11/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150788377 | CMS |
| Integra LifeSciences Corporation | $22.37 | 07/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1140098757 | CMS |
| MIMEDX Group, Inc. | $400.00 | 05/01/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1140266161 | CMS |
| MIMEDX Group, Inc. | $200.00 | 06/03/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1140266163 | CMS |
| MIMEDX Group, Inc. | $200.00 | 07/01/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1140266165 | CMS |
| MIMEDX Group, Inc. | $200.00 | 09/03/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1140266167 | CMS |
| MIMEDX Group, Inc. | $200.00 | 12/02/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1140266169 | CMS |
| Novo Nordisk Inc | $21.63 | 02/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097775812 | CMS |
| Organon Llc | $22.89 | 02/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136258860 | CMS |
| Organon Llc | $27.61 | 10/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136258864 | CMS |
| PFIZER INC. | $19.39 | 05/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131518545 | CMS |
| PFIZER INC. | $25.44 | 10/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132073100 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.